Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 17, 2016 02:00 ET | Source: Karolinska Development AB

Karolinska Development – Q3 2016 Interim Report - invitation to conference call and webcast

Please dial in at one of the following numbers a few minutes before the start of the conference call: From Sweden: +46 (0) 8 505 564 74 From the US: +1 855 753 22...
November 15, 2016 02:00 ET | Source: Karolinska Development AB

Karolinska Development company Modus Therapeutics’ ongoing clinical study with sevuparin in sickle cell disease expands to include adolescent patients

Details from the Modus Therapeutics press release follow: A planned independent Data Safety Monitoring Board (DSMB) review has been conducted in the multi-centre, randomized Phase II clinical...
November 07, 2016 02:00 ET | Source: Karolinska Development AB

Karolinska Development company Modus Therapeutics granted U.S. patents for sickle cell disease drug candidate sevuparin

Details from the Modus Therapeutics press release follow: The two patents granted by the United States Patent and Trademark Office (USPTO) will provide key intellectual property protection in the...
November 03, 2016 03:00 ET | Source: Karolinska Development AB

Karolinska Developments bolag Umecrine Cognition meddelar positiva Fas 1-data med GR3027 mot hepatisk encefalopati

Detaljer från Umecrine Cognitions pressrelease: “Vi är mycket uppmuntrade av den farmakodynamiska effektmålet hos GR3027 i våra Fas 1-försök, samt med dess fördelaktiga säkerhets-...
November 03, 2016 03:00 ET | Source: Karolinska Development AB

Karolinska Development company Umecrine Cognition announces positive Phase 1 data with GR3027 in hepatic encephalopathy

Details from the Umecrine Cognition press release follow: “We are very encouraged by the pharmacodynamic effect of GR3027 in our Phase 1 trials, along with its favorable safety and...
October 27, 2016 03:32 ET | Source: Karolinska Development AB

Karolinska Development portfolio company Promimic AB appoints new Chairman and Directors to its Board

Tord Lendau brings to Promimic more than 32 years’ of international leadership and board experience from innovative, rapid growth companies. Most recently, he was General Manager at Sandvik MedTech,...
October 20, 2016 02:00 ET | Source: Karolinska Development AB

Karolinska Development company Dilaforette to change name to Modus Therapeutics and announces intention to conduct an Initial Public Offering

Modus Therapeutics (www.modustx.com) is a clinical-stage drug development company developing new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in rare...
October 20, 2016 02:00 ET | Source: Karolinska Development AB

Karolinska Developments bolag Dilaforette byter namn till Modus Therapeutics och meddelar sin avsikt att genomföra en börsintroduktion

Modus Therapeutics (www.modustx.com) är ett läkemedelsbolag i det kliniska skedet som utvecklar nya farmaceutiska terapier för att återställa begränsat blodflöde och syretransport i ovanliga...
October 19, 2016 02:00 ET | Source: Karolinska Development AB

Karolinska Development portfolio company Promimic and Danco announce completion of US production line for HAnano Surface medical implant coating

Details from the Promimic press release follow: Promimic and Danco entered a strategic partnership in March 2016 under which Danco became the preferred process partner for Promimic for...
October 10, 2016 03:00 ET | Source: Karolinska Development AB

Karolinska Development portfolio company Aprea Therapeutics updates clinical data from Phase Ib trial of APR-246 in ovarian cancer.

Efficacy and safety data for APR-246 in high grade serous ovarian cancer presented at ESMO 2016 annual meeting Details from the Aprea announcement follow: The Phase Ib clinical study...